HC Surgical Specialists has reported earnings of $3.97 million for the 1HFY2026 ended Nov 30, 2025, up 17.5% y-o-y.
Revenue declined 1.6% y-o-y for 1HFY2026 to $9.78 million, and earnings per share came in 17.7% y-o-y higher at 2.59 cents.
Earnings grew due to non-operational items, including fair value gain on financial assets at fair value through profit or loss of about $910,000, offset by non-existence of fair value loss on derivative financial instruments.
This fair value gain on financial assets was due to the increase in share price of Medinex and Singapore Paincare Holdings; partially offset by the decrease in share price of Aoxin Q&M Dental Group.
The group’s share of results of associates also increased by $98,000 in 1HYFY2026.
The group reported a decrease in other income due to the decrease of grants, decrease in interest income, and non-existence of compensation income. Employee benefits expense also increased for this reporting period due to increased headcount, regular increment and higher locum doctor’s fees relating to Medistar Services.
The directors are declaring an interim dividend of 0.90 cents per ordinary share.
The group notes that the Ministry of Health recently announced major changes to the Integrated Shield Plan (IP) riders which will take effect from April 1. These new requirements are unlikely to have an immediate material impact on the group’s financial position, the group says.
Shares in HC Surgical Specialists closed 1 cent lower or 2.778% down at 35 cents on Jan 13.
